CP‑31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression

Liu,Ling; Yang,Li; Chang,Hui; Chen,Yan‑Nan; Zhang,Feng; Feng,Shuo; Peng,Juan; Ren,Chen‑Chen; Zhang,Xiao‑An

doi:10.3892/ijo.2019.4681

CP‑31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression

Authors:
- Ling Liu
- Li Yang
- Hui Chang
- Yan‑Nan Chen
- Feng Zhang
- Shuo Feng
- Juan Peng
- Chen‑Chen Ren
- Xiao‑An Zhang
View Affiliations

Affiliations: Department of Gynecologic Oncology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Laboratory of Tumor Precision Medicine, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Imaging, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 9, 2019 https://doi.org/10.3892/ijo.2019.4681
Pages: 942-954
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial cancer (EC) is one of the most common malignancies of the female reproductive system, and metastasis is a major cause of mortality. In this study, we aimed to explore the role of CP‑31398 in the migration, invasion and apoptosis of EC cells by its regulation of the expression of the murine double minute 2 (MDM2) gene. For this purpose, EC tissues and adjacent normal tissues were collected, and the positive expression rate of MDM2 in these tissues was assessed. Subsequently, the cellular 50% inhibitory concentration (IC50) of CP‑31398 was measured. The EC RL95‑2 and KLE cell lines had a higher MDM2 expression and were thus selected for use in subsequent experiments. The EC cells were then treated with CP‑31398 (2 µg/ml), and were transfected with siRNA against MDM2 or an MDM2 overexpression plasmid in order to examine the effects of CP‑31398 and MDM2 on EC cell activities. The expression of p53, p21, Bad, Bax, B‑cell lymphoma‑2 (Bcl‑2), cytochrome c (Cyt‑c), caspase‑3, Cox‑2, matrix metalloproteinase (MMP)‑2 and MMP‑9 was measured to further confirm the effects of CP‑31398 on cell migration, invasion and apoptosis. Our results indicated that MDM2 was highly expressed in EC tissues. Notably, EC cell viability decreased with the increasing concentrations of CP‑31398. The EC cells treated with CP‑31398 or siRNA against MDM2 exhibited an increased apoptosis and a suppressed migration and invasion, corresponding to an increased expression of p53, p21, Bad, Bax, Cyt‑c and caspase‑3, as well as to a decreased expression of Bcl‑2, Cox‑2, MMP‑2 and MMP‑9. Moreover, treatment with CP‑31398 and siRNA against MDM2 further enhanced these effects. Taken together, the findings of this study indicate that the CP‑31398‑mediated downregulation of MDM2 may suppress EC progression via its inhibitory role in EC cell migration, invasion and resistance to apoptosis. Therefore, treatment with CP‑31398 may prove to be possible therapeutic strategy for EC.

View Figures

View References

1	Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
2	Sorosky JI: Endometrial cancer. Obstet Gynecol. 120:383–397. 2012. View Article : Google Scholar : PubMed/NCBI
3	Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S and Lam EW: Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 70:367–377. 2010. View Article : Google Scholar
4	May K, Bryant A, Dickinson HO, Kehoe S and Morrison J: Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 1:CD0075852010.
5	Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, et al: A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 17:921–929. 2008. View Article : Google Scholar : PubMed/NCBI
6	Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT and Nout RA: Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 51:1742–1750. 2015. View Article : Google Scholar : PubMed/NCBI
7	Sanz-Chávez TL, Vilar-Compte D, de Nicola-Delfín L and Meneses-García A: Overweight, obesity, diabetes, and hypertension in endometrial cancer. Rev Med Inst Mex Seguro Soc. 51:326–329. 2013.In Spanish.
8	Shafiee MN, Chapman C, Barrett D, Abu J and Atiomo W: Reviewing the molecular mechanisms which increase endo-metrial cancer (EC) risk in women with polycystic ovarian syndrome (PCOS): Time for paradigm shift? Gynecol Oncol. 131:489–492. 2013. View Article : Google Scholar : PubMed/NCBI
9	Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K and Herzog TJ: Contemporary management of endometrial cancer. Lancet. 379:1352–1360. 2012. View Article : Google Scholar : PubMed/NCBI
10	Johnson WD, Muzzio M, Detrisac CJ, Kapetanovic IM, Kopelovich L and McCormick DL: Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs. Toxicology. 289:141–150. 2011. View Article : Google Scholar : PubMed/NCBI
11	Kapetanovic IM, Muzzio M, McCormick DL, Thompson TN, Johnson WD, Horn TL, Mohammed A, Rao CV and Kopelovich L: Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats. Cancer Chemother Pharmacol. 69:1301–1306. 2012. View Article : Google Scholar : PubMed/NCBI
12	Madka V, Zhang Y, Li Q, Mohammed A, Sindhwani P, Lightfoot S, Wu XR, Kopelovich L and Rao CV: p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice. Neoplasia. 15:966–974. 2013. View Article : Google Scholar : PubMed/NCBI
13	He XX, Zhang YN, Yan JW, Yan JJ, Wu Q and Song YH: CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo. Tumour Biol. 37:807–815. 2016. View Article : Google Scholar
14	He X, Kong X, Yan J, Yan J, Zhang Y, Wu Q, Chang Y, Shang H, Dou Q, Song Y, et al: CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo. Tumour Biol. 36:1437–1444. 2015. View Article : Google Scholar : PubMed/NCBI
15	Fiorini C, Menegazzi M, Padroni C, Dando I, Dalla Pozza E, Gregorelli A, Costanzo C, Palmieri M and Donadelli M: Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis. 18:337–346. 2013. View Article : Google Scholar
16	Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L and Athar M: Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 70:6566–6576. 2010. View Article : Google Scholar : PubMed/NCBI
17	Hashemi M, Omrani M, Eskandari-Nasab E, Hasani SS, Mashhadi MA and Taheri M: A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast cancer in Zahedan, Southeast Iran. Iran Biomed J. 18:245–249. 2014.PubMed/NCBI
18	Lu X, Yan C, Huang Y, Shi D, Fu Z, Qiu J and Yin Y: Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo. Oncotarget. 7:37177–37191. 2016.PubMed/NCBI
19	Roszak A, Misztal M, Sowińska A and Jagodziński PP: Murine double-minute 2 homolog single nucleotide polymorphisms 285 and 309 in cervical carcinogenesis. Mol Diagn Ther. 19:235–244. 2015. View Article : Google Scholar : PubMed/NCBI
20	Gu J, Tang Y, Liu Y, Guo H, Wang Y, Cai L, Li Y and Wang B: Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo. Cancer Lett. 343:200–209. 2014. View Article : Google Scholar
21	Nakajima N, Ito Y, Yokoyama K, Uno A, Kinukawa N, Nemoto N and Moriyama M: The Expression of murine double minute 2 (MDM2) on Helicobacter pylori-infected intestinal metaplasia and gastric cancer. J Clin Biochem Nutr. 44:196–202. 2009. View Article : Google Scholar : PubMed/NCBI
22	Demma MJ, Wong S, Maxwell E and Dasmahapatra B: CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem. 279:45887–45896. 2004. View Article : Google Scholar : PubMed/NCBI
23	Haltia UM, Bützow R, Leminen A and Loukovaara M: FIGO 1988 versus 2009 staging for endometrial carcinoma: A comparative study on prediction of survival and stage distribution according to histologic subtype. J Gynecol Oncol. 25:30–35. 2014. View Article : Google Scholar : PubMed/NCBI
24	Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
25	Karber G: Determination of median lethal dose. Arch Exp Pathol Pharmacol. 162:4801931.
26	Halevy T, Czech C and Benvenisty N: Molecular mechanisms regulating the defects in fragile X syndrome neurons derived from human pluripotent stem cells. Stem Cell Reports. 4:37–46. 2015. View Article : Google Scholar :
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
28	Ayuk SM, Abrahamse H and Houreld NN: The role of photo-biomodulation on gene expression of cell adhesion molecules in diabetic wounded fibroblasts in vitro. J Photochem Photobiol B. 161:368–374. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS and Huang C: MicroRNA profiling of human gastric cancer. Mol Med Rep. 2:963–970. 2009.PubMed/NCBI
30	Fang Y, Chen H, Hu Y, Li Q, Hu Z, Ma T and Mao X: Burkholderia pseudomallei-derived miR-3473 enhances NF-κB via targeting TRAF3 and is associated with different inflammatory responses compared to Burkholderia thailandensis in murine macrophages. BMC Microbiol. 16:2832016. View Article : Google Scholar
31	Bell DW: Novel genetic targets in endometrial cancer. Expert Opin Ther Targets. 18:725–730. 2014. View Article : Google Scholar : PubMed/NCBI
32	Bansal N, Yendluri V and Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Contr. 16:8–13. 2009. View Article : Google Scholar
33	Planagumà J, Liljeström M, Alameda F, Bützow R, Virtanen I, Reventós J and Hukkanen M: Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol. 42:57–67. 2011. View Article : Google Scholar
34	Yoneda T, Kuboyama A, Kato K, Ohgami T, Okamoto K, Saito T and Wake N: Association of MDM2 SNP309 and TP53 Arg 72Pro polymorphisms with risk of endometrial cancer. Oncol Rep. 30:25–34. 2013. View Article : Google Scholar : PubMed/NCBI
35	Tang W, He X, Chan Y and Luo Y: Lack of association between p53 codon 72 polymorphism and endometrial cancer: A meta-analysis. Cancer Epidemiol. 36:e153–e157. 2012. View Article : Google Scholar : PubMed/NCBI
36	Dorjgochoo T, Xiang YB, Long J, Shi J, Deming S, Xu WH, Cai H, Cheng J, Cai Q, Zheng W, et al: Association of genetic markers in the BCL-2 family of apoptosis-related genes with endometrial cancer risk in a Chinese population. PLoS One. 8:e609152013. View Article : Google Scholar : PubMed/NCBI
37	Ma X, Hui Y, Lin L, Wu Y, Zhang X and Liu P: Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak J Med Sci. 31:280–284. 2015. View Article : Google Scholar : PubMed/NCBI
38	Wang XF, Zhao YB, Wu Q, Sun ZH and Li HJ: Triptolide induces apoptosis in endometrial cancer via a p53 independent mitochondrial pathway. Mol Med Rep. 9:39–44. 2014. View Article : Google Scholar
39	Jiang D, Cho W, Li Z, Xu X, Qu Y, Jiang Z, Guo L and Xu G: miR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR. Biomed Pharmacother. 96:535–544. 2017. View Article : Google Scholar : PubMed/NCBI
40	Haupt S, Vijayakumaran R, Miranda PJ, Burgess A, Lim E and Haupt Y: The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol. 9:53–61. 2017.PubMed/NCBI
41	Deb SP, Singh S and Deb S: MDM2 overexpression, activation of signaling networks, and cell proliferation. Subcell Biochem. 85:215–234. 2014. View Article : Google Scholar : PubMed/NCBI
42	Peng Q, Mo C, Qin A, Lao X, Chen Z, Sui J, Wu J, Zhai L, Yang S, Qin X, et al: MDM2 SNP309 polymorphism contributes to endo-metrial cancer susceptibility: Evidence from a meta-analysis. J Exp Clin Cancer Res. 32:852013. View Article : Google Scholar
43	Köhrmann A, Kammerer U, Kapp M, Dietl J and Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 9:1882009. View Article : Google Scholar : PubMed/NCBI
44	Li H, Qiu Z, Li F and Wang C: The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis. Oncol Lett. 14:5865–5870. 2017.PubMed/NCBI
45	Hu X, Li D, Zhang W, Zhou J, Tang B and Li L: Matrix metal-loproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 286:1537–1543. 2012. View Article : Google Scholar : PubMed/NCBI
46	Grybos A and Bar J: The relationships between the immunoex-pression of KAI1, MMP-2, MMP-9 and steroid receptors expression in endometrial cancer. Folia Histochem Cytobiol. 52:187–194. 2014. View Article : Google Scholar
47	Yang Y, Zhu J, Gou H, Cao D, Jiang M and Hou M: Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepato-cellular carcinoma (HCC). Med Oncol. 28:796–803. 2011. View Article : Google Scholar
48	Hasegawa K, Torii Y, Ishii R, Oe S, Kato R and Udagawa Y: Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch Gynecol Obstet. 284:1515–1521. 2011. View Article : Google Scholar : PubMed/NCBI
49	Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS and Munkarah A: Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 126:382–394. 2010. View Article : Google Scholar
50	Vogler M: BCL2A1: The underdog in the BCL2 family. Cell Death Differ. 19:67–74. 2012. View Article : Google Scholar :
51	Du C, Zhang X, Yao M, Lv K, Wang J, Chen L, Chen Y, Wang S and Fu P: Bcl-2 promotes metastasis through the epithelial-to-mesenchymal transition in the BCap37 medullary breast cancer cell line. Oncol Lett. 15:8991–8898. 2018.PubMed/NCBI
52	Dong P, Xu Z, Jia N, Li D and Feng Y: Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer. 8:1032009. View Article : Google Scholar : PubMed/NCBI
53	Jongen VH, Briët JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AG and Nijman HW: Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer. 19:670–676. 2009. View Article : Google Scholar : PubMed/NCBI
54	Mahapatra G, Varughese A, Ji Q, Lee I, Liu J, Vaishnav A, Sinkler C, Kapralov AA, Moraes CT, Sanderson TH, et al: Phosphorylation of Cytochrome c Threonine 28 Regulates Electron Transport Chain Activity in Kidney: IMPLICATIONS FOR AMP KINASE. J Biol Chem. 292:64–79. 2017. View Article : Google Scholar :
55	Gosslau A, Pabbaraja S, Knapp S and Chen KY: Trans- and cis-stilbene polyphenols induced rapid perinuclear mitochondrial clustering and p53-independent apoptosis in cancer cells but not normal cells. Eur J Pharmacol. 587:25–34. 2008. View Article : Google Scholar : PubMed/NCBI
56	Sayeed I, Parvez S, Wali B, Siemen D and Stein DG: Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism for better neuroprotective effects of allo-pregnanolone over progesterone. Brain Res. 1263:165–173. 2009. View Article : Google Scholar : PubMed/NCBI
57	Hu L, Zhang H, Bergholz J, Sun S and Xiao ZX: MDM2/MDMX: Master negative regulators for p53 and RB. Mol Cell Oncol. 3:e11066352016. View Article : Google Scholar : PubMed/NCBI
58	Nunobiki O, Ueda M, Yamamoto M, Toji E, Sato N, Izuma S, Okamoto Y, Torii K and Noda S: Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell. 22:101–106. 2009. View Article : Google Scholar : PubMed/NCBI
59	Wang H, Bao W, Jiang F, Che Q, Chen Z, Wang F, Tong H, Dai C, He X, Liao Y, et al: Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGγ. Cancer Lett. 360:269–279. 2015. View Article : Google Scholar : PubMed/NCBI
60	Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T and Sakuragi N: p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis. 24:471–483. 2007. View Article : Google Scholar : PubMed/NCBI
61	Wischhusen J, Naumann U, Ohgaki H, Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
62	Moll UM and Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 1:1001–1008. 2003.
63	Wang W, Takimoto R, Rastinejad F and El-Deiry WS: Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol. 23:2171–2181. 2003. View Article : Google Scholar : PubMed/NCBI